Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
Date:3/11/2011

ients greater precision in their efforts to fine tune their glucose control. Patients treated with insulin pumps represent a significant portion of the market, manage their disease aggressively, and are early adopters of new treatments and technologies.
  • Halozyme's two Phase 2 clinical studies that compare treatment with an insulin analog alone to Analog-PH20 for twelve weeks each completed patient enrollment this past January. Results from these two studies will be available to Halozyme internally during the third quarter of 2011.
  • Roche completed patient enrollment of its Phase 3 registration study for Herceptin® SC (trastuzumab subcutaneous) in December for the treatment of HER2-positive breast cancer and has stated it expects to have results from this study by the end of 2011. In February 2011, Roche began patient dosing of the Phase 3 MabThera® SC (rituximab subcutaneous) clinical trial in patients with follicular non-Hodgkin's lymphoma. Roche has stated it expects to file for the approval of Herceptin SC and MabThera SC in the EU during 2012.
  • Baxter completed its Phase 3 clinical trial of HyQ, immunoglobulin with rHuPH20, at the end of 2010. Baxter has stated it plans to submit a BLA filing during the second half of 2011 and to launch the product in 2012. The worldwide market for immunoglobulin totals approximately $6 billion and Baxter commands a sizeable share of the market.

  • Fourth Quarter and Year End 2010 Financial ResultsThe net loss for the fourth quarter of 2010 was $16.9 million, or $0.17 per share, compared with a net loss for the fourth quarter of 2009 of $12.7 million, or $0.14 per share. The net loss for the year ended December 31, 2010 was $53.2 million, or $0.56 per share, compared to a net loss of $58.4 million, or $0.67 per share, for the year 2009.

  • Revenue for the fourth quarter of 2010 was $3.6 million, compared to $6.4 million for the
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
    2. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
    3. Halozyme Therapeutics Realigns Management
    4. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
    5. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
    6. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
    7. Halozyme Therapeutics Announces Public Offering of Common Stock
    8. Halozyme Provides HYLENEX® Product Reintroduction Update
    9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
    10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
    11. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/1/2015)... DALLAS , April 1, 2015 /PRNewswire/ ... Research Report on Global Azithromycin Industry and ... Drug Industry reports added to Pharmaceutical category ... analysis, the report introduces Azithromycin basic information, ... industry overview, policy analysis, and news analysis, ...
    (Date:4/1/2015)... 1, 2015 Jintian Pharmaceutical Group Limited ("Jintian ... Mr. Jin Dongtao, chairman and executive director purchased 40,000,000 ... of the existing entire issued share capital of the ... with the total amount of approximately HK$113 million. Upon ... will increase from 45.17% to 47.17%. ...
    (Date:4/1/2015)... , Mar. 30, 2015 Research and Markets ... the "An Introduction to the Medical Device Directives" ... provides a detailed introduction to the European medical device ... are covered, the involvement of Notified Bodies, how to ... It will also cover the documentation necessary to apply ...
    Breaking Medicine Technology:Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 2Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 3Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 4Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 5An Introduction to the Medical Device Directives Training: London, UK - 13th, 14th, 15th of May 2015 2
    ... Inc. (NYSE: WPI ) today announced ... reached a settlement with Mallinckrodt Inc. on outstanding ... Mallinckrodt,s Exalgo® (Hydromorphone Hydrochloride Extended-Release ) tablets.  Mallinckrodt ... the United States District Court for the District ...
    ... Pa., Jan. 26, 2012   ProPhase Labs, Inc., the ... October, November and December winners of its "Share Your Cause ... provides financial aid on charitable work in US communities, has ... Buddies of Milwaukie, OR; and Hannah,s Home of Mentor, OH ...
    Cached Medicine Technology:Watson Reaches Settlement with Mallinckrodt Over Exalgo(R) 2Cold-EEZE® Cold Remedy Announces Winners in its "Share Your Cause Not Your Cold" Campaign 2Cold-EEZE® Cold Remedy Announces Winners in its "Share Your Cause Not Your Cold" Campaign 3Cold-EEZE® Cold Remedy Announces Winners in its "Share Your Cause Not Your Cold" Campaign 4
    (Date:4/1/2015)... 2015 Taking an important step forward ... for Nursing Commission for Nursing Education Accreditation (NLN CNEA) ... first NLN CNEA Board of Commissioners. Working with executive ... 15-member board will provide leadership and direction to accreditation ... decisions for nursing programs that seek accreditation from the ...
    (Date:4/1/2015)... IL, Bethesda, MD, Alexandria, VA (PRWEB) April 01, ... Clinical Pathology (ASCP), the College of American Pathologists ... the American Society of Clinical Oncology (ASCO) today ... on the use of molecular marker testing for ... evidence-based guideline will help establish standard molecular marker ...
    (Date:4/1/2015)... April 01, 2015 Dr Roz Kamani, ... she is now offering her patients an opportunity to ... can participate in “Beauty Days”, which is an exclusive ... Roz Kamani’s Kitsilano Skin Care Clinic. It is attended ... patients about the latest products and services that are ...
    (Date:4/1/2015)... 2015 Tempaper has joined forces with ... giving campaign that will raise critical funds to help ... disease across the United States. , Throughout the month ... Tempaperdesigns.com will automatically receive free domestic ground shipping ... urgently needed progress to children and adults affected by ...
    (Date:4/1/2015)... IQ Formulations , one of the most highly regarded ... U.S., today is commending GNC for taking steps to boost ... herbal supplements.* GNC vowed that its new processes will look ... labeling on its products. , In response to this ... Jay Cohen said: , “In a lightly-regulated industry where ...
    Breaking Medicine News(10 mins):Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 2Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 4Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 3Health News:IQ Formulations Applauds GNC for Enhancing Its Testing and Quality Control Processes for Herbal Supplements 2
    ... 2009 Oral-B(R) Stages, the dental,professional,s #1 recommended ... a campaign in recognition of National Children,s Dental ... about the state of children,s,oral health in America, ... parents and,healthcare providers alike. In fact, tooth ...
    ... MILL VALLEY, Calif., Feb. 12 Kovarus, Inc., a ... cycling shop in,Mill Valley, today jointly announced the launch ... cycling while also increasing awareness of a good cause,the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080708/AQTU138LOGO ) , ...
    ... Cohen, president of Cleveland-based PRN Funding, LLC, participated ... on to do three more educational factoring videos. ... via PRN Funding,s unique factoring YouTube channel ( ... Channel in place, PRN Funding,s three featured factoring ...
    ... Perspective and Future DirectionsRALEIGH, N.C., Feb. 12 ... Clinical Research Organization, will host a prominent panel of ... February 25. Discussions will include case scenarios on cutting ... applicable to other fields of infectious disease research.The agenda ...
    ... Services, Inc. (NYSE: WST ) announced today ... before the market opens on Thursday, February 19, 2009 ... the results and business expectations at 9:00 a.m. Eastern ... or (210)839-8398. The passcode is WST.A live broadcast of ...
    ... Alert and Focused on and off the Racetrack -KENILWORTH, ... ), maker of the top-selling allergy medicine, CLARITIN, announces ... of NASCAR star and long-time allergy sufferer Carl Edwards. ... symptoms, will drive the No. 99 CLARITIN Ford Fusion ...
    Cached Medicine News:Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 2Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 3Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 4Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 5Health News:Oral-B Addresses Children's Oral Health Needs at All Stages of Development During National Children's Dental Health Month 6Health News:Biking for Fun, Sport, and Brain Tumor Awareness 2Health News:Biking for Fun, Sport, and Brain Tumor Awareness 3Health News:PRN Funding Introduces the PRN Funding YouTube Channel 2Health News:PRA International Speaking Event: Rational Drug Design and Development in Infectious Diseases 2Health News:West to Host 2008 Fourth Quarter Conference Call 2Health News:Claritin(R) Renews Sponsorship With Allergy Sufferer and NASCAR Star Carl Edwards 2Health News:Claritin(R) Renews Sponsorship With Allergy Sufferer and NASCAR Star Carl Edwards 3
    The ENDO CLOSE™ trocar site closure device has application in laparoscopic procedures for approximation of tissues and percutaneous suturing for closing incision sites....
    This ENDOLOOP suture has a suture type - 0 PDSII and a 1.5 inch diameter....
    ... long ligature inserted into a plastic tube. The plastic ... the other. The suture protrudes from the narrow end ... knot which becomes secure after the device is activated. ... the scored end of the plastic tube. The scored ...
    ... difficile Panel is an enzyme immunoassay used ... antigen (glutamate dehydrogenase) and toxin A in ... as an aid in the diagnosis of ... of the Triage Microbiology product line, designed ...
    Medicine Products: